

# Accepted Manuscript

Efficacy and safety of glycopyrrolate/eFlow<sup>®</sup> (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials

Edward Kerwin, James F. Donohue, Thomas Goodin, Robert Tosiello, Alistair Wheeler, Gary T. Ferguson

PII: S0954-6111(17)30210-X

DOI: [10.1016/j.rmed.2017.07.011](https://doi.org/10.1016/j.rmed.2017.07.011)

Reference: YRMED 5207

To appear in: *Respiratory Medicine*

Received Date: 9 March 2017

Revised Date: 30 June 2017

Accepted Date: 17 July 2017



Please cite this article as: Kerwin E, Donohue JF, Goodin T, Tosiello R, Wheeler A, Ferguson GT, Efficacy and safety of glycopyrrolate/eFlow<sup>®</sup> (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials, *Respiratory Medicine* (2017), doi: 10.1016/j.rmed.2017.07.011.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Efficacy and safety of glycopyrrolate/eFlow<sup>®</sup> (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 3 and 4 randomized controlled trials

## Authors

Edward Kerwin <sup>a,\*</sup>, James F. Donohue <sup>b</sup>, Thomas Goodin <sup>c</sup>, Robert Tosiello <sup>c</sup>, Alistair Wheeler <sup>c,†</sup>, Gary T. Ferguson <sup>d</sup>

## Affiliations

<sup>a</sup>Clinical Research Institute of Southern Oregon, Inc., Medford, OR, USA

<sup>b</sup>University of North Carolina School of Medicine, Chapel Hill, NC, USA

<sup>c</sup>Sunovion Pharmaceuticals Inc., Marlborough, MA, USA

<sup>d</sup>Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA

## Corresponding author

\*Edward Kerwin, MD

Clinical Research Institute of Southern Oregon, Inc.

3860 Crater Lake Avenue

Medford, OR 97504

Email: ekerwin@criresearch.com

Phone: (541) 858-1003

<sup>†</sup>Alistair Wheeler's present address: Spyryx Biosciences, Inc., Durham, NC, USA.

Download English Version:

<https://daneshyari.com/en/article/8820063>

Download Persian Version:

<https://daneshyari.com/article/8820063>

[Daneshyari.com](https://daneshyari.com)